Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

AFMD Company Profile and Key Details

NASDAQ : AFMD

Affimed N.V.

$1.04
-0.01-0.95%
At Close 4:00 PM
50
BESG ScoreESG Rating

AFMD Stock Price Chart

Stock Price Today

Affimed N.V. (AFMD) stock declined over -0.95%, trading at $1.04 on NASDAQ, down from the previous close of $1.05. The stock opened at $1.06, fluctuating between $1.00 and $1.06 in the recent session.

Stock Snapshot

1.05
Prev. Close
1.06
Open
15.84M
Market Cap
15.23M
Number of Shares
1.0027
Day Low
1.06
Day High
-0.22
P/E Ratio
85.51%
Free Float in %
-4.76
EPS (TTM)
3.87
Book Value
-7.63
Cash Flow per Share
39.83K
Volume

Stock Price History Chart

DateOpenHighLowCloseVolume
Feb 27, 20251.061.061.001.0439.83K
Feb 26, 20251.011.051.001.0577.8K
Feb 25, 20251.011.020.981.0069.39K
Feb 24, 20251.051.051.001.0232.86K
Feb 21, 20251.021.051.001.0464.6K
Feb 20, 20251.061.061.001.0276.3K
Feb 19, 20251.051.091.051.0671.67K
Feb 18, 20251.061.071.031.0776.46K
Feb 14, 20251.051.081.011.06112.56K
Feb 13, 20250.991.090.991.06209.93K
Feb 12, 20251.041.060.981.0087.01K
Feb 11, 20251.041.061.021.0472.62K
Feb 10, 20251.061.071.001.0478.18K
Feb 07, 20251.051.061.041.0572.72K
Feb 06, 20251.031.071.021.0594.91K
Feb 05, 20251.021.051.001.0263.13K
Feb 04, 20250.991.030.971.01108.99K
Feb 03, 20251.011.010.950.98104.84K
Jan 31, 20251.001.060.981.01134.1K
Jan 30, 20251.001.010.920.98154.3K

Contact Details

Heidelberg, 69120

Germany

Website: https://www.affimed.comContact: 496 221 674360

About Company

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Company Information

Employees76
Beta2.15
Sales or Revenue$8.28M
5Y Sales Change%-0.859%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Frequently Asked Questions

What is the current Affimed N.V. (AFMD) stock price?

Affimed N.V. (NASDAQ: AFMD) stock price is $1.04 in the last trading session. During the trading session, AFMD stock reached the peak price of $1.06 while $1.00 was the lowest point it dropped to. The percentage change in AFMD stock occurred in the recent session was -0.95% while the dollar amount for the price change in AFMD stock was -$0.01.

AFMD's industry and sector of operation?

The NASDAQ listed AFMD is part of Biotechnology industry that operates in the broader Healthcare sector. Affimed N.V. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AFMD?

Dr. Wolfgang Fischer
MD, Chief Operating Officer & Member of Management Board
Mr. Alexander Fudukidis
Head of Investor Relations & Director of Investor Relations
Dr. Uwe Reusch
Head of Cell Culture
Dr. Arndt Justus Georg Schottelius M.D., Ph.D.
Chief Scientific Officer & Member of Management Board
Dr. Adi Hoess
Chief Executive Officer, MD & Member of Management Board
Ms. Denise Mueller
Chief Bus. Officer & Member of Management Board
Dr. Andreas Harstrick M.D.
Chief Medical Officer & Member of Management Board
Mary Beth Sandin
Vice President of Marketing & Communications
Prof. Melvyn Little
Founder & Consultant
Mr. Michael Wolf
Head of Fin. & Admin.
Dr. Arndt J. G. Schottelius M.D., Ph.D.
Chief Scientific Officer & Member of Management Board
Dr. Adi Hoess M.D., Ph.D.
Chief Executive Officer, MD & Member of Management Board
Mr. Angus W. Smith
Chief Financial Officer & Member of Management Board

How AFMD did perform over past 52-week?

AFMD's closing price is 13.04% higher than its 52-week low of $0.92 where as its distance from 52-week high of $8.95 is -88.38%.

How many employees does AFMD have?

Number of AFMD employees currently stands at 76.

Link for AFMD official website?

Official Website of AFMD is: https://www.affimed.com

How do I contact AFMD?

AFMD could be contacted at phone 496 221 674360 and can also be accessed through its website. AFMD operates from Technologiepark, Heidelberg, 69120, Germany.

How many shares of AFMD are traded daily?

AFMD stock volume for the day was 39.83K shares. The average number of AFMD shares traded daily for last 3 months was 321.07K.

What is the market cap of AFMD currently?

The market value of AFMD currently stands at $15.84M with its latest stock price at $1.04 and 15.23M of its shares outstanding.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph